A Phase II, Prospective, Randomized, Observer-masked, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of Two Concentrations Compared to Placebo for the Treatment of Dry Eye Disease

NCT01239069 Phase 2 COMPLETED

Investigate the Safety and Efficacy of Two Concentrations of DE-110 Compared to Placebo for the Treatment of Dry Eye Disease

Details

Lead sponsor	Santen Inc.
Phase	Phase 2
Status	COMPLETED
Enrolment	140
Start date	2010-11
Completion	2011-10

Conditions

• Dry Eye

Interventions

• DE-110 ophthalmic suspension high dose
• DE-110 ophthalmic suspension low dose
• Placebo

Primary outcomes

• Efficacy of DE-110 — 12 weeks

Countries

United States